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We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF)
inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean
number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in
5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months
(𝑛 = 15; 𝑃 = 0.001), 105.3 microns at 1 year (𝑛 = 10; 𝑃 = 0.03), and 157.6 microns at 2 years (𝑛 = 7; 𝑃 = 0.08). BCVA improved by
3.3 lines at 6 months after therapy (𝑛 = 26; 𝑃 < 0.001), 2.8 lines (𝑛 = 20; 𝑃 = 0.01) at 1 year, and 3.1 lines (𝑛 = 13; 𝑃 = 0.049) at 2
years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.
1. Introduction
Choroidal osteoma is a rare ossifying choroidal tumor involv-
ing mostly young healthy females in the second decade of life
[1–6]. The benign mass appears as a deep yellowish lesion
with distinct geographic borders at the juxtapapillary or
macular region, with branching “spider” vessels on its surface.
The diagnosis is confirmed with the presence of calcification
on ultrasonography and computed tomography. Vision is
often compromised by gradual atrophy of the overlying retina
[6] or by accumulation of either subretinal fluid or subretinal
hemorrhage with or without choroidal neovascularisation
(CNV). Frequent exams are recommended for patients with
choroidal osteoma for early detection of a subretinal neo-
vascular membrane and potential treatment. Therapies have
included laser photocoagulation [7, 8], excision of CNV [9],
photodynamic therapy (PDT) [10–14], and transpupillary
thermal therapy (TTT) [15, 16].
We evaluated clinically and by optical coherence tomog-
raphy (OCT) [6, 17] the role of intravitreal injections of
vascular endothelial growth factor (VEGF) antagonist in the
therapy of CNV in choroidal osteomas after their use in some
case reports [18–29].
2. Materials and Methods
We reviewed retrospectively the files of subjects having
choroidal osteoma who were treated with intravitreal injec-
tions of bevacizumab or ranibizumab for active CNV. Intrav-
itreal injections of 0.05mL or 0.1mL of either bevacizumab
(25mg/mL) or ranibizumab (10mg/mL) were administered
in the office as 3 initial consecutive doses or based on OCT
response depending on physician preference. Intravitreal
injection was performed using a 30-gauge needle in a sterile
manner after topical anesthesia and povidone instillation in
the lower conjunctival sac. Bevacizumab (Avastin, Genentech
Inc, San Francisco, CA) aliquots were prepared in the hospital
pharmacies of the corresponding institutions. Ranibizumab
(Lucentis, Genentech Inc, San Francisco, CA) was also
used in some centers. A standardized spreadsheet was used
to collect the clinical data. Photodynamic therapy (PDT)
with intravenous verteporfin (standard dose 6mg/m2 body
surface area or half the standard dose) (Visudyne, Novartis
AG, Basel, Switzerland) was administered simultaneously in
some patients based solely on individual physician prefer-
ence. Institutional review board/ethics committee approval
and patients’ signed informed consents were obtained for
this study. In addition, this study has been performed in
accordance with the ethical standards laid down in the
1964 Declaration of Helsinki for research involving human
subjects. The offlabel use of both drugs and their potential
risks and benefits was discussed extensively with all patients.
Best corrected visual acuity (BCVA) was assessed using
either ETDRS or Snellen charts and listed as logarithm
of the minimum angle of resolution (logMar) equivalents.
Retreatment was done when there was recurrent activity
evaluated by fundus examination, fluorescein angiography
(leakage, growth of CNV), or optical coherence tomography.
Differences between final and initial BCVA were tested
using paired Student 𝑡-test. Improvement of visual acuity
was defined as any fraction of a line of improvement on
the ETDRS chart. We did not compare the initial to the
posttreatment central foveal thickness because of the different
OCT machines among centers as well as because of the need
for thickness analysis by gender, race, age, and refractive
status [17]. We analyzed only the absolute decrease in central
foveal thickness. One patient had bilateral osteoma with
CNV arising in one eye and several years later in the fellow
eye and hence both eyes were included in the statistical
analysis. Significance was set at the 0.05 level. We used SPSS
19 version for statistical calculation (IBM, Armonk, New
York, 2010). Literature review till April 2014 (using both
PubMed and Google Scholar) was added to ascertain the
visual results in this rare disease entity with bevacizumab
or ranibizumab therapies [18–29]. Collaborators and one of
us (AMM) measured the CNV size on digital fluorescein
transit films and the osteoma basal diameter on color films
in reference to the horizontal disc diameter by using a
transparent reticule or ruler on the computer screen.
3. Results
We treated 26 eyes from 25 patients with a mean age at
presentation of 29 years (range 8–57 years) with 16 women
and 9 men having the following racial distribution: 18
Caucasians, 4 Indians, and 3 Asians. Laterality included 15
right eyes (57.7%) and 11 left eyes (42.3%) (Table 1). Mean
follow-up was 26 months (range 6–71 months, median 20
months). The longest osteoma basal diameter varied from
1 to 10 disc diameters with a mean of 4.6 disc diameters.
Bevacizumab was injected in 17 eyes (65.4%), ranibizumab
in 5 eyes (19.2%), and a combination of both drugs in 4 eyes
(15.4%). The volume injected was 0.05mL in 24 eyes (92.3%)
and 0.1mL in 2 eyes (7.7%). The mean number of injections
was 4.5 (range 1–17, median 3) at the last follow-up.Themean
number of injections at 6 months, 12 months, and 24 months
was, respectively, 2.4 (𝑛 = 26), 3.2 (𝑛 = 20), and 5.5 (𝑛 = 13).
CNV was subfoveal in 14 eyes (53.8%), juxtafoveal in 5 eyes
(19.2%), extrafoveal in 5 eyes (19.2%), and peripapillary in
2 eyes (7.7%). The mean size of CNV was 1.3 disc diameter
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Table 2: Mean lines of visual acuity improvement after anti-VEGF injections (excluding 6 PDT & 2 chronic CNV eyes)∗.
Initial (preinjection) 6 months 12 months 18 months 24 months
Number of eyes 18 18 14 10 7
Mean line of improvement 0.77 3.3 3.4 3.2 4.9
Paired comparison (P value) 0.006 0.01 0.03 0.03
∗VEGF = vascular endothelial growth factor; CNV = choroidal neovascularization; PDT = photodynamic therapy.
Table 3: Summary profile comparing patients who underwent PDT plus anti-VEGF to patients who had anti-VEGF therapy alone (excluding
chronic cases of CNV) at the 6-month follow-up∗.
Category Age Gender(M/F)
Mean
follow-up CNV location
Initial vision
(logMar)
Final vision
(logMar)
Number of PDT
sessions
Number of
injections
PDT group 𝑛 = 6 27 2/4 32 months Subfoveal 5Juxtafoveal 1 0.65 0.40 1.8 (1–4) 3.9
No PDT group 𝑛 = 18 32 7/11 24 months
Subfoveal 8
Juxtafoveal 4
Extrafoveal 4
Peripapillary 2
0.77 0.42 0 4.4
∗VEGF = vascular endothelial growth factor; CNV = choroidal neovascularization; M = male; F = female; PDT = photodynamic therapy; logMar = logarithm
of the minimum angle of resolution.
(range 0.3–3 disc diameter; 𝑛 = 22 eyes). There was no
correlation between the size of the choroidal osteoma and
initial visual acuity (Pearson correlation = 0.19; two-tailed
probability 𝑃 = 0.36). Eight cases presented with subretinal
hemorrhage and the rest with subretinal fluid. Photodynamic
therapy (PDT) was given concomitant with initial anti-VEGF
injection in 3 eyes (11.5%), repeated twice in 2 eyes (7.7%) and
repeated 3 times in one eye (3.8%).
Mean central foveal thickness was 447 microns (𝑛 = 20
eyes) at baseline, 339 microns (𝑛 = 20 eyes) at 6 months after
intraocular injection, 320 microns (𝑛 = 11 eyes) at 1 year, and
265 microns (𝑛 = 9 eyes) at 2 years. Fifteen of 16 eyes showed
a decrease in central foveal thickness at 6 months of therapy.
By paired comparison, the mean decrease from baseline was
119.7 microns at 6 months (𝑛 = 15; 𝑃 = 0.001), 105.3 microns
at 1 year (𝑛 = 10; 𝑃 = 0.03), and 157.6 microns at 2 years
(𝑛 = 7; 𝑃 = 0.08). BCVA improved by 3.3 lines at 6 months
after therapy (𝑛 = 26; 𝑃 < 0.001) (20 eyes had improvement
in BCVA, 3 had stable vision, and 3 had loss of vision at the
6-month follow-up), 2.8 lines (𝑛 = 20; 𝑃 = 0.01) at 1 year, and
3.1 lines (𝑛 = 13; 𝑃 = 0.049) at 2 years. No ocular or systemic
adverse events were noted.
To analyze the effect of anti-VEGF alone (without PDT) in
more or less acute cases with CNV, we eliminated 2 eyes that
had chronic signs of CNV (atrophic thin retina, very large
amount of submacular fluid) and 6 eyes that had concomitant
PDT, leaving 18 eyes for analysis. Visual acuity improved from
0.77 (6/35 or 20/118) to 0.44 (6/17 or 20/55) at 6 months
(𝑛 = 18) (𝑃 = 0.006), a gain of 3.3 lines (Table 2). Thirteen
eyes (50.0%) had improvement in BCVA, 2 eyes (7.7%) had
stable vision, and 3 eyes (11.5%) had loss of vision at the 6-
month follow-up. Also, there was visual improvement of 3.4
lines at 1 year (0.67 to 0.34; 𝑛 = 14; 𝑃 = 0.01) and 4.9 lines at
2 years (0.79 to 0.30; 𝑛 = 7; 𝑃 = 0.03). Moreover, by paired
comparison, the decrease in central foveal thickness from
baseline was 139.5 microns at 6 months (𝑛 = 11; 𝑃 = 0.002),
123.7 microns at 12 months (𝑛 = 6; 𝑃 = 0.1), and 196.4
microns at 24 months (𝑛 = 5; 𝑃 = 0.1). In the other group
of concomitant PDT, BCVA improved by 3.9 lines at the 6-
month follow-up from 0.65 (6/27 or 20/90) to 0.26 (6/11 or
20/36) (𝑃 = 0.04) (Table 3). In addition, Table 4 details the
characteristics of 13 cases of choroidal osteomas treated with
anti-VEGF injections published in the literature.
4. Discussion
Visual impairment in eyes with choroidal osteoma can be
attributable to several factors including subfoveolar location,
foveal edema, photoreceptor degeneration [6], serous retinal
detachment, and CNV [3]. Without any therapy, choroidal
osteoma-associated CNV can result in a progressive and
permanent loss of visual acuity. CNV occurs in 31% to 47%
of patients followed for 10 years [3, 6].
The cause for the development of a CNV in eyes with a
choroidal osteoma has not been determined, but choroidal
osteomas with overlying hemorrhage or irregular surface
appeared at higher risk of developing a CNV [3]. Osteomas,
in general, have a high bone turnover reflecting their high
metabolic rate and hence may steal blood supply from adja-
cent tissues, especially overlying retinal pigment epithelium
which may upregulate the expression of VEGF. Presumably,
attenuation and disruption of the retinal pigment epithelium-
Bruch membrane complex overlying the choroidal osteoma
allows over years for the development of CNV.
There is no standard treatment for a choroidal osteoma.
Various treatments for CNV have been tried, but they do
not usually halt visual loss. The results of one study showed
that photocoagulation of an extrafoveal classic CNVwas suc-
cessful in closing CNV in 25% of treated eyes [2]. However,
photocoagulation can stimulate rapid vascular remodeling
and anastomoses in choroidal osteoma [3]. Another study
reported that the CNV can be surgically removed, but
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the postoperative visual acuity was poor at 6/95 (20/320)
[4]. PDT has been partially successful in treating CNV in
eyes with choroidal osteoma. Earlier studies showed that,
6 months after a single PDT, the metamorphopsia can
resolve completely; in one study, the visual acuity was not
changed [5] and in another study it improved from 6/60
(20/200) to 6/6 (20/20) [6]. Another study reported that
four PDT applications led to closure of the CNV, but the
final vision was 6/35 (20/120) [7]. PDT has successfully
caused closure of extrafoveal CNV in choroidal osteoma
[6]. Laser photocoagulation or PDT in choroidal osteomas
with or without CNV may carry the risk of decalcification
of choroidal osteoma [10]. Shields et al. [10] proposed that
photodynamic therapy could be a therapeutic modality for
choroidal neovascularization and induction of decalcification
of extrafoveal osteoma to prevent tumor growth into the
foveola. However, these results should not be extrapolated
to subfoveal choroidal osteoma because decalcification of
subfoveal choroidal osteoma could result in worse visual
acuity because of loss of retinal pigment epithelium and
choroidal perfusion [1, 3, 6, 10].
TTT was effective in obstructing the CNV but the visual
outcome was also poor. An earlier report indicates that, at
10 months after one TTT application, vision improved from
6/24 (20/80) to 6/18 (20/60), and the vision was maintained
with a scarred CNV [8]. In another report, the final visual
acuity was 6/60 (20/200) after three TTT applications [9].
Combination therapy of PDT and anti-VEGF injections
reduced the number of anti-VEGF injections, hence reducing
the risk of vision-threatening complications.The reduction in
the number of injections was marginal in the current series
(Table 2) and there was little difference between the use of
PDT or its omission, although a direct comparison could not
be done because of the small number in the current series as
well as difference in protocols in administration of both anti-
VEGF agents and PDT.
Ahmadieh and Vafi [18] reported the dramatic response
of a juxtafoveal CNV associated with choroidal osteoma to
a single intravitreal injection of bevacizumab in a 19-year-
old female with visual improvement from 6/60 (20/200)
to 6/7.5 (20/25) and resolution of metamorphopsia with
the treatment effect persisting during a 9-month follow-
up period. Subsequently, the positive effects of intravitreal
anti-VEGF injections were confirmed in 10 cases with CNV
associated with choroidal osteoma (Table 4). Kubota-Taniai
et al. [25] described the long-term effect of 2 intravitreal
bevacizumab injections (4 months apart) in complete angio-
graphic regression of CNV for a period of 4 years in a 12-
year-old girl with visual improvement from 6/30 (20/100) to
6/9 (20/30). We noted similar response in 8 out of 26 eyes
needing only 1 to 2 injections with maintenance of visual
improvement. It is possible that small osteomas or osteoma
that do not grow do not need further injections. This issue
was not studied in the current protocol. The growth of the
tumor during followup was not assessed also and it could be
that growing tumors secrete more VEGF and require more
injections. The young age of the patients with osteoma may
partly explain the good response to anti-VEGF therapies. A
single case had retinal pigment epithelial tear after anti-VEGF
injection [29].
5. Conclusions
The inherent limitations of this study include its small num-
ber, retrospective nature, limited follow-up, lack of a standard
therapeutic protocol, lack of a control group, and difference in
OCT machines among centers. However, our results suggest
that intravitreal bevacizumab or ranibizumab might be an
effective therapeutic option for choroidal osteoma-associated
CNV that is causing deterioration in vision, particularly
when the CNV is juxtafoveolar or subfoveolar in location. In
eyes where the CNV is not subfoveolar, adjunctive therapies
such as laser photocoagulation or PDT could be considered.
Further studies with longer follow-up are indicated to con-
firm the long-term efficacy of bevacizumab or ranibizumab
monotherapy in choroidal osteomas.
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